Evaluated for: Dry macular degeneration
How it works: Rheopheresis (RHEO) is an experimental procedure being tested in the treatment of dry macular degeneration. The aim of the RHEO procedure is to filter the blood of patients with dry macular degeneration in hopes of removing certain substances (large proteins, fatty particles, etc.) that are known to be associated with the progression of macular degeneration. These substances are thought to reduce the flow of blood to areas of the eye that are critical for vision. By removing these substances and improving blood flow to the eye, RHEO is thought to benefit patients by improving the supply of oxygen and nutrients, which is critical for the health of the cells of the macula, the area of the eye affected by macular degeneration.
Most common side effects: Hypotension (low blood pressure), nausea, dizziness, fainting, and bruising at the sites of IV insertion may occur.
A thoughtful evaluation must be performed by a physician before taking any medications, over-the-counter drugs, supplements, or herbs. The American Health Assistance Foundation does not endorse any of these medications, vitamins, or herbs. A qualified physician should make an informed decision based on each person's medical history and current prescriptions. The medication summaries provided do not include all of the information important for patient use and should not be used as a substitute for professional medical advice. The prescribing physician should be consulted concerning any questions that you have.
The information provided in this section of our website was obtained from the National Institutes of Health (NIH)/National Eye institute (NEI), the Food and Drug Administration (FDA), the National Library of Medicine, and research scientists specializing in macular degeneration.
Reviewed on 2/14/2008